ReviewJournal of clinical practice and research2026
Current Vaccination Principles and Practices in Adult Cancer Patients.
Review in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adults with cancer are at a substantially increased risk of infectious complications due to malignancy-related immune dysregulation and the immunosuppressive effects of anticancer therapies. Vaccine-preventable infections remain a significant cause of morbidity and mortality despite advances in oncologic care. This review summarizes current evidence and international guideline recommendations on vaccination strategies in adult patients with solid tumors. Inactivated and recombinant vaccines are generally safe and should be administered according to standard schedules, preferably before the initiation of immunosuppressive therapy. Although immune responses may be attenuated during treatment, available data support a meaningful clinical benefit in reducing severe infections and hospitalizations. Live attenuated vaccines are contraindicated during significant immunosuppression and should be considered only after documented immune reconstitution. Optimizing vaccination outcomes requires individualized scheduling, attention to treatment-related immune effects, and immunization of household contacts. Proactive, guideline-based vaccination should be integrated into routine oncology care to reduce infection-related complications and support treatment continuity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.